news

 

December 2016 Crowdfunding campaign for a novel treatment for malignant mesothelioma

 
Crowdfunding campaign for a novel treatment for malignant mesothelioma

AROMICS Biotech has launched a crowdfunding campaign, through the Capital Cell platform, with the aim of raising at least 300,000 euros to complete preclinical development of NAX035, a novel compound for the treatment of Malignant Mesothelioma.

Malignant Mesothelioma is an aggressive, highly-resistant tumor directly linked to exposure asbestos

For more details, please visit: www.capitalcell.net

https://www.youtube.com/watch?v=LoloAP8oIMs